aqua vac erm, koncentrat do sporządzania zawiesiny do kąpieli dla pstrągów tęczowych koncentrat do sporządzania zawiesiny do kąp
intervet international b.v. - inaktywowane komórki yersinia ruckeri typ 1 szczep hagermana - koncentrat do sporządzania zawiesiny do kąpieli
woda do wstrzykiwań csl behring - rozpuszczalnik do sporządzania leków parenteralnych
csl behring gmbh - aqua pro injectione - rozpuszczalnik do sporządzania leków parenteralnych - -
latanoprost bijon 50 mikrogramów/ml krople do oczu, roztwór
bijon medica, uab - latanoprostum - krople do oczu, roztwór - 50 mikrogramów/ml
contril 60 mg/10 ml syrop
us pharmacia sp. z o.o. - levodropropizinum - syrop - 60 mg/10 ml
euphorbium s - aerozol do nosa, roztwór
biologische heilmittel heel gmbh - euphorbium + pulsatilla + mucosa nasalis suis d8 + argentum nitricum + luffa operculata + mercurius bijodatus d12 + sinusitis-nosode d13 + hepar sulfuris - aerozol do nosa, roztwór - -
euphorbium sn - krople doustne, roztwór
biologische heilmittel heel gmbh - hepar sulfuris + argentum nitricum + euphorbium + pulsatilla + luffa operculata + hydrargyrum biiodatum - krople doustne, roztwór - -
luffa compositum - heel tabletki
biologische heilmittel heel gmbh - aralia racemosa d1; arsenum iodatum d8; lobelia inflata; luffa operculata - tabletki
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
co-fineria 50 mg + 500 mg tabletki o zmodyfikowanym uwalnianiu
medical pharmaquality s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 500 mg
co-fineria 50 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
medical pharmaquality s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 1000 mg